Twist Bioscience Corporation has completed an upsized $300 million public offering of common stock, providing fresh capital for research, manufacturing expansion and product development. Priced at $96 per share in August 2026, the transaction is not a conventional IPO because Twist is already publicly traded, but it represents a significant capital raise for a biotechnology company seeking to scale its synthetic biology platform and expand its commercial reach.

Twist Bioscience’s Synthetic Biology Business

Twist Bioscience develops and manufactures synthetic DNA using a proprietary silicon-based technology platform. Its products are used by pharmaceutical and biotechnology companies, academic researchers and other organizations for applications including drug discovery, antibody development, next-generation sequencing and biological research.

Chief Executive Officer Emily M. Leproust leads the company, which has built its growth strategy around making DNA synthesis faster, more scalable and potentially more cost-efficient. Twist has expanded beyond basic DNA production into higher-value applications, including antibody discovery and partnerships supporting pharmaceutical research. Its business model combines sales of biological products with technology and strategic relationships that can broaden the potential commercial applications of its platform.

Public Offering and Market Structure

Twist initially proposed a $250 million offering before pricing an upsized transaction involving 3.125 million shares at $96 each. The company raised $300 million in gross proceeds, while the underwriting group exercised an option for an additional 468,750 shares. The common stock trades on the Nasdaq Global Select Market under the ticker TWST.

The offering does not involve an IPO price range, projected market capitalization or an $8 million fundraising target because Twist is an established public company. Goldman Sachs, William Blair, Leerink Partners and Guggenheim Securities acted as representatives of the underwriting group. Twist expects to deploy the proceeds alongside existing cash and marketable securities toward research and development, manufacturing capacity, product expansion, working capital and general corporate purposes.

Synthetic Biology Market Creates Expansion Opportunities

The broader synthetic biology market is attracting investment as advances in DNA design, sequencing, artificial intelligence and biological engineering expand the potential applications of engineered genetic material. Twist’s platform gives it exposure to several growth areas rather than relying solely on one pharmaceutical product or therapeutic program.

Drug discovery represents an important opportunity because pharmaceutical companies increasingly use engineered biological systems to accelerate research and develop new antibodies and other biologic candidates. Twist’s ability to supply DNA at scale could therefore position the company to benefit from increasing demand for faster research cycles and more sophisticated biological design.

Risks and Challenges

The investment case remains dependent on execution. Synthetic biology is highly competitive, and technological advances can change the economics of DNA synthesis and research services quickly. Twist must also invest heavily in manufacturing capacity and research while converting customer demand and partnerships into sustainable revenue growth and improving profitability.

The equity offering creates additional share dilution, while biotechnology stocks can experience significant valuation volatility as expectations around growth, innovation and future cash generation change. Investors must also consider the risk that expanded capacity does not generate returns quickly enough to justify the capital committed to it.

What to Watch After the Capital Raise

The central issue for investors is whether Twist can use the new capital to move beyond rapid top-line expansion and demonstrate improving operating leverage. Revenue growth, manufacturing utilization, gross margins, demand for synthetic DNA and progress in drug-discovery partnerships will be key indicators. The latest financing gives Twist greater resources to pursue its strategy, but the longer-term market valuation will depend on whether its technology can translate into durable commercial scale and a clearer path toward profitability.